"CREST Syndrome" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A mild form of LIMITED SCLERODERMA, a multi-system disorder. Its features include symptoms of CALCINOSIS; RAYNAUD DISEASE; ESOPHAGEAL MOTILITY DISORDERS; sclerodactyly, and TELANGIECTASIS. When the defect in esophageal function is not prominent, it is known as CRST syndrome.
| Descriptor ID |
D017675
|
| MeSH Number(s) |
C06.405.117.119.500.204 C14.907.617.812.500 C14.907.823.225 C17.300.799.801.500 C17.800.784.801.500 C18.452.174.130.204
|
| Concept/Terms |
CREST Syndrome- CREST Syndrome
- CREST Syndromes
- Syndrome, CREST
- Calcinosis, Raynaud's phenomenon, Esophageal dismobility, Sclerodactyly, Telangiectasia Syndrome
CRST Syndrome- CRST Syndrome
- CRST Syndromes
- Syndrome, CRST
- Calcinosis-Raynaud Phenomenon-Sclerodactyly-Telangiectasia
- Calcinosis Raynaud Phenomenon Sclerodactyly Telangiectasia
- Phenomenon-Sclerodactyly-Telangiectasia, Calcinosis-Raynaud
|
Below are MeSH descriptors whose meaning is more general than "CREST Syndrome".
Below are MeSH descriptors whose meaning is more specific than "CREST Syndrome".
This graph shows the total number of publications written about "CREST Syndrome" by people in this website by year, and whether "CREST Syndrome" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "CREST Syndrome" by people in Profiles.
-
PACK syndrome: A case series and review. Am J Med Sci. 2023 04; 365(4):321-328.
-
Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis. Arthritis Rheum. 2013 Nov; 65(11):2917-27.
-
Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases. J Immunol. 1999 Jul 15; 163(2):1066-72.
-
Office evaluation and treatment of Raynaud's phenomenon. Cleve Clin J Med. 1995 Jan-Feb; 62(1):51-61.